BMS and AZ strengthen their joint diabetes franchise

Bristol-Myers Squibb Company and AstraZeneca Plc are set to strengthen their diabetes franchise through a staged deal in which BMS will acquire Amylin Pharmaceuticals Inc and thereafter exploit Amylin’s portfolio with AstraZeneca